Shots:
- The EC has approved Daybu (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in pts (≥5yrs.) across all 30 EEA states
- Approval was based on the results from the P-III (LAVENDER) study, which showed improvements in core features of Rett syndrome, as measured by RSBQ & CGI-I scale co-1EPs
- Daybu, a synthetic analog of the N-terminal tripeptide of insulin-like growth factor 1, will undergo pricing & reimbursement negotiations with EU national authorities as Acadia works toward potential patient access across the EU
Ref: Businesswire | Image: Acadia | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
